Sugi Predict

Sugi Predict / Compounds / SCHEMBL1786207

SCHEMBL1786207

SCHEMBL1786207

O=C(NCCCCN1CCCC1)Nc1snc(OCc2c(F)cc(Br)cc2F)c1C(=O)O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 5/20 0.86
▸ PDGFRB P09619 4/20 0.86
▸ FLT1 P17948 3/20 0.86
▸ PLK4 O00444 1/20 0.86
▸ AURKA O14965 1/20 0.86
▸ EPHB6 O15197 1/20 0.86
▸ RIPK2 O43353 1/20 0.86
▸ STK10 O94804 1/20 0.86
▸ MAP4K4 O95819 1/20 0.86
▸ ABL1 P00519 1/20 0.86
▸ EGFR P00533 1/20 0.86
▸ INSR P06213 1/20 0.86
▸ LCK P06239 1/20 0.86
▸ FYN P06241 1/20 0.86
▸ YES1 P07947 1/20 0.86
▸ LYN P07948 1/20 0.86
▸ RET P07949 1/20 0.86
▸ MET P08581 1/20 0.86
▸ ROS1 P08922 1/20 0.86
▸ BCR P11274 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Osi-632 SCHEMBL187261 0.93 KDR (1.00) KDRPDGFRBFLT1PLK4AURKA
Osi-632 SCHEMBL438781 0.92 KDR (0.98) KDRPDGFRBFLT1PLK4AURKA
Osi-632 SCHEMBL5705524 0.92 KDR (0.98) KDRPDGFRBFLT1PLK4AURKA
SCHEMBL377945 0.92 KDR (0.84) KDRPDGFRBFLT1PLK4AURKA
Osi-632 SCHEMBL5705560 0.91 KDR (0.94) KDRPDGFRBFLT1PLK4AURKA
SCHEMBL5342761 0.91 KDR (0.72) KDRPDGFRBFLT1PLK4AURKA
Osi-632 SCHEMBL5705534 0.90 KDR (0.94) KDRPDGFRBFLT1PLK4AURKA
Osi-632 SCHEMBL5705655 0.89 KDR (0.90) KDRPDGFRBFLT1PLK4AURKA
SCHEMBL5344408 0.89 KDR (0.69) KDRPDGFRBFLT1PLK4AURKA
SCHEMBL5351091 0.88 KDR (0.68) KDRPDGFRBFLT1PLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817031-A1 COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT Trustees Of Tufts College (US) 2014-12-31 — — EP claimed
WO-2013126799-A1 COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT TRUSTEES OF TUFTS COLLEGE (US) 2013-08-29 — — WO claimed
EP-3560509-B1 SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF CHILDRENS MEDICAL CENTER (US) 2024-01-31 — — EP disclosed
EP-4306123-A2 SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF Children's Medical Center Corporation (US) 2024-01-17 — — EP disclosed
EP-3560509-A1 SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF Children's Medical Center Corporation (US) 2019-10-30 — — EP disclosed
EP-2793921-B1 SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF CHILDRENS MEDICAL CENTER (US) 2019-04-24 — — EP disclosed
EP-2817031-A1 COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT Trustees Of Tufts College (US) 2014-12-31 — — EP disclosed
US-20140336387-A1 SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF CONCERT PHARMACEUTICALS, INC. (US) 2014-11-13 — — US disclosed
EP-2793921-A2 SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF Children's Medical Center Corporation (US) 2014-10-29 — — EP disclosed
WO-2013126799-A1 COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT TRUSTEES OF TUFTS COLLEGE (US) 2013-08-29 — — WO disclosed
WO-2013096868-A2 SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2013-06-27 — — WO disclosed
EP-1337521-B1 SALTS OF AN ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS PFIZER PROD INC (US) 2006-09-27 — — EP disclosed
WO-2005105080-A1 COMBINATION THERAPY TO TREAT DIARRHEA INDUCED BY CANCER TREATMENT PFIZER PRODUCTS INC. (US) 2005-11-10 — — WO disclosed
WO-2005102327-A1 DOSAGE FORMS AND METHODS OF TREATMENT USING VEGFR INHIBITORS PFIZER PRODUCTS INC. (US) 2005-11-03 — — WO disclosed
US-20050245456-A1 Combination therapy to prevent and treat diarrhea induced by cancer treatment PFIZER INC 2005-11-03 — — US disclosed
US-20050234115-A1 Dosage forms and methods of treatment using VEGFR inhibitors PFIZER INC. 2005-10-20 — — US disclosed
US-6831091-B2 Anticancer agents PFIZER INC. 2004-12-14 — — US disclosed
EP-1337521-A1 SALTS OF AN ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS Pfizer Products Inc. (US) 2003-08-27 — — EP disclosed
US-20020151573-A1 Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production PFIZER INC. 2002-10-17 — — US disclosed
WO-2002044158-A1 SALTS OF A ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS PFIZER PRODUCTS INC. (US) 2002-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151573-A1 Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production CPS1, FH, CS KDR 2187/4885PDGFRB 2017/4885FLT1 930/4885
US-20140336387-A1 SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF COMT, DRD2, DRD3 KDR 1708/4885PDGFRB 2334/4885FLT1 3192/4885
US-20050234115-A1 Dosage forms and methods of treatment using VEGFR inhibitors FLT1, FLT4, KDR KDR 3/4885PDGFRB 22/4885FLT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.